Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Approved That Predicts Coronary Heart Disease Risk

By LabMedica International staff writers
Posted on 30 Dec 2014
A new test has been approved that can predict an individual's risk of coronary heart disease, the primary cause of death for both men and women in the USA, and the test is hailed as particularly effective for African American women. More...


The test works by measuring the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that is an indicator of vascular inflammation, in a blood sample. Vascular inflammation is a sign of plaque accumulation in the arteries, and this build-up of plaque can clog the arteries and cause coronary heart disease.

According to the US Food and Drug Administration (FDA; Silver Springs, MD, USA), the test has been cleared for use in both men and women with no history of heart disease, but studies have shown it is more accurate in predicting coronary heart disease risk (CHD) in women. Patients with Lp-PLA2 activity over 225 nmol/min/mL in their blood are deemed high risk of a CHD event, such as a heart attack or stroke. Patients with Lp-PLA2 activity below 225 nmol/min/mL are classed as lower risk for a CHD event.

The diaDexus PLAC Test for Lp-PLA2 (diaDexus; South San Francisco, CA, USA) is a sandwich enzyme immunoassay that uses two highly specific monoclonal antibodies for the direct measurement of Lp-PLA2 concentration in human plasma and serum. The FDA in their review included the PLAC Test for Lp-PLA2 Activity Validation Study, in which the test was administered on 4,598 participants aged 45 to 92 years who had no history of CHD. Of these participants, 58.3% were women and 41.5% were black. The study scientists followed the participants for an average of 5.3 years, during which time they recorded the occurrence of CHD events among each individual.

The results of the study revealed that 7% of participants with Lp-PLA2 activity higher than 225 nmol/min/mL experienced a CHD event, compared with only 3.3% of participants with Lp-PLA2 activity lower than 225 nmol/min/mL. On analyzing the team's data by subgroups, the FDA found that the rate of CHD events was much higher among African American women whose Lp-PLA2 activity levels were higher than 225 nmol/min/mL, compared with other subgroups with similar Lp-PLA2 activity. CHD events were also found to be more common among women with Lp-PLA2 activity levels over 225 nmol/min/mL than men with such levels.

Alberto Gutierrez, PhD, Director of FDA’s Office of In Vitro Diagnostics, said, “A cardiac test that helps better predict future CHD risk in women, and especially African American women, may help health care professionals identify these patients before they experience a serious CHD event, like a heart attack. We hope the clearance of this test will improve preventative care and reduce CHD-related mortality and morbidity in these patients.”

Related Links:

US Food and Drug Administration
diaDexus 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.